Medicure Company Profile (CVE:MPH)

About Medicure

Medicure logoMedicure Inc. (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company's primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company's United States subsidiary, Medicure Pharma, Inc. AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS). The Company is also engaged in the development of TARDOXAL for neurological disorders, such as Tardive Dyskinesia (TD). The Company has completed Phase IIa stage of development for TARDOXAL. The Company is also developing Transdermal AGGRASTAT, a cure for acute cardiology. Transdermal AGGRASTAT is in preclinical-stage of development.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: CVE
  • Symbol: MPH
  • CUSIP:
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $N/A
  • 200 Day Moving Average: $N/A
  • 52-Week Range: C$4.73 - C$10.67
  • Trailing P/E Ratio: N/A
  • P/E Growth: N/A
  • Market Cap: $N/A
  • Outstanding Shares: 15,532,000
Additional Links:

Analyst Ratings

Consensus Ratings for Medicure (CVE:MPH) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: N/A

Analysts' Ratings History for Medicure (CVE:MPH)
DateFirmActionRatingPrice TargetDetails
5/4/2016M PartnersReiterated RatingBuyView Rating Details
1/12/2016MackieBoost Price TargetBuyC$8.00View Rating Details
(Data available from 2/24/2015 forward)


Earnings History for Medicure (CVE:MPH)
No earnings announcements for this company have been tracked by


Earnings Estimates for Medicure (CVE:MPH)
Current Year EPS Consensus Estimate: $0.32 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.13$0.13$0.13
Q2 20161$0.13$0.13$0.13
Q3 20161$0.05$0.05$0.05
Q4 20161$0.18$0.18$0.18
Q1 20171$0.26$0.26$0.26
Q2 20171$0.27$0.27$0.27
Q3 20171$0.29$0.29$0.29
Q4 20171$0.31$0.31$0.31
(Data provided by Zacks Investment Research)


Dividend History for Medicure (CVE:MPH)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Medicure (CVE:MPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/17/2016Albert David FriesenDirectorBuy1,100C$5.55C$6,105.00
3/16/2016Graeme William MerchantInsiderBuy1,650C$6.40C$10,560.00
3/11/2016Graeme William MerchantInsiderBuy1,500C$6.30C$9,450.00
3/8/2016Graeme William MerchantInsiderSell6,300C$7.01C$44,163.00
9/9/2015Elliott International CapitalInsiderSell1,426,002C$2.98C$4,249,485.96
1/7/2015Albert David FriesenDirectorBuy2,900C$2.01C$5,829.00
(Data available from 1/1/2013 forward)


Latest Headlines for Medicure (CVE:MPH)
News IconHow Analysts Feel About Medicure Inc After Today's Gap Down? - Fair Herald (CVE:MPH) - January 18 at 7:11 PM
News IconFollow The Canada Stock: Medicure Inc (MPH) Jumped 3.86% on Dec 21 - Herald KS (CVE:MPH) - December 21 at 7:27 PM logoReminder - Morguard Real Estate Investment Trust (MRT-UN) Goes Ex-Dividend Soon (CVE:MPH) - December 12 at 6:44 PM
News IconInvestor Hub: Looking at Shares of Medicure Inc. (TSXV:MPH) - Highland Digest (CVE:MPH) - December 9 at 6:37 PM logoMedicure Closes Acquisition of Majority Interest in Apicore - MarketWatch (CVE:MPH) - December 2 at 6:19 PM logoCross Lake Minerals : Closes Debt Financing with Crown Capital Partners for Apicore Purchase (CVE:MPH) - November 21 at 11:31 AM
News IconMedicure Inc. MPH Financial and Strategic SWOT Analysis Review Prices from USD $300 (CVE:MPH) - November 21 at 11:31 AM logoCross Lake Minerals : Crown Capital Partners Completes $60.0 Million Term Loan with Medicure Inc. (CVE:MPH) - November 19 at 8:52 AM logoCrown Capital Partners Completes $60.0 Million Term Loan with Medicure Inc. (CVE:MPH) - November 18 at 9:04 AM logoMedicure Exercises Option to Acquire Majority Interest in Apicore (CVE:MPH) - November 18 at 9:04 AM logoThese fund managers look outside the index in expensive times (CVE:MPH) - November 17 at 5:53 PM logoReminder - Morguard North American Residential Real Estate Investment Trust (MRG-UN) Goes Ex-Dividend Soon (CVE:MPH) - October 26 at 6:15 PM logoReminder - InterRent Real Estate Investment Trust (IIP-UN) Goes Ex-Dividend Soon (CVE:MPH) - September 27 at 10:49 AM logoNew AGGRASTAT® Product Format Gains FDA Approval (CVE:MPH) - September 1 at 6:09 PM
News IconMedicure Release: FDA Approves New AGGRASTAT Product Format (CVE:MPH) - September 1 at 6:09 PM logoMedicure Reports Second Quarter 2016 Financial Results (CVE:MPH) - August 11 at 9:26 AM logoMedicure Inc. (MPH.V) (CVE:MPH) - February 24 at 10:28 AM logoUndervalued And Underfollowed; Medicure Is My Favorite Pharma Small Cap (CVE:MPH) - February 17 at 10:03 AM logoMedicure To Present At Cantech Investment Conference (CVE:MPH) - January 22 at 9:43 AM logoMedicure Inc V.MPH.H (CVE:MPH) - January 17 at 9:01 AM


What is Medicure's stock symbol?

Medicure trades on the Canadian Venture Exchange (CVE) under the ticker symbol "MPH."

How do I buy Medicure stock?

Shares of Medicure and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

How much does a share of Medicure stock cost?

One share of Medicure stock can currently be purchased for approximately C$9.00.

Medicure (CVE:MPH) Chart for Friday, February, 24, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Medicure (CVE:MPH)

Earnings History Chart

Earnings by Quarter for Medicure (CVE:MPH)

Dividend History Chart

Dividend Payments by Quarter for Medicure (CVE:MPH)

Last Updated on 2/24/2017 by Staff